Race, medicine, and social justice: Pharmacogenetics, diversity, and the case of BiDil

Review of Policy Research

Volumn 25, Issue 1, 2008, Pages 53-69

  Jordan, Sara R ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Health policy; Pharmacogenetics; Racial disparities; Social justice

Indexed keywords

HEALTH CARE; HIGH TECHNOLOGY INDUSTRY; MEDICINE; POLICY ANALYSIS; RACIAL DISPARITY; REGULATORY FRAMEWORK; SOCIAL JUSTICE; TECHNOLOGY POLICY;

EID: 38649093922     PISSN: 1541132X     EISSN: 15411338     Source Type: Journal    
DOI: 10.1111/j.1541-1338.2008.00309.x     Document Type: Article

References (91)

1. The African American cardiologist who heads the Jackson heart study. (2002). Journal of Blacks in Higher Education, 37(Autumn), 45.
2. Anderson, R. T., Press, N., Tucker, D. C., Snively, B. M., Wenzel, L., Ellis, S. D., etal. (2005). Patient acceptability of genotypic testing for hemochromatosis in primary care. Genetic Medicine, 7, 557-563.
3. Aronow, W. S., Ahn, C., & Kronzon, I. (1999). Comparison of incidences of congestive heart failure in older African Americans, Hispanics and whites. The American Journal of Cardiology, 84, 611-612.
4. Balakrishnan, S. (2004). BiDil: Raising more than nitric oxide. Harvard Science Review, Winter, 74-76.
5. Banquet, C. R., Comminsky, P., Daniel Mullins, C., & Mishra, S. I. (2006). Recruitment and participation in clinical trials: Socio-demographic, rural/urban and health care access predictors. Cancer Detection and Prevention, 30(1), 24-33.
6. Bamshad, W. E., Wooding, S., Salisbury, B. A., & Stephens, J. C. (2004). Deconstructing the relationship between genetics and race. National Revue of Genetics, 5, 598-608.
7. Best practices for the licensing of genomic inventions: Final notice. (2005). 70 C.F.R. § 68, 18413-18417.
8. Bhopal, R. (1997). Is research into ethnicity and health racist, unsound or important science? British Medical Journal, 314, 1751.
9. Bhopal, R. (2004). Glossary of terms relating to ethnicity and race: For reflection and debate. Journal of Epidemiology and Community Health, 58, 441-445.
10. Bobbio, N. (2000). In praise of meekness: Essays on ethics and politics. (T. Chataway, trans.). Cambridge, UK: Polity Press.
11. Boden, W. E., Ziesche, S., Carson, P. E., Conrad, C. H., Syat, D., & Cohn, J. N. (1996). Rationale and design of the third vasodilator-heart failure trial (V-HeFT III). American Journal of Cardiology, 77, 1078-1082.
12. Bowman, J. E., Corbie-Smith, G., Lurie, P., Wolfe, S. M., Caplan, A. L., Annas, G. J., etal. (1999). Tuskegee as metaphor. Science, 285 (July), 47-50.
13. Burchard, E. G., et al. (2003). The importance of race and ethnic background in biomedical research and practice. New England Journal of Medicine, 348, 1170-1175.
14. Byrd, W. M., & Clayton, L. A. (2000). An American health dilemma, volume one. A medical history of African Americans and the problem of race: Beginnings to 1900. New York: Routledge.
15. Carson, P. E., Johnson, G. R., Dunkman, W. B., Fletcher, R. D., Farrell, L., & Cohn, J. N. (1993). The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation, 87(Suppl. 6), 102-110.
16. Carson, P., Johnson, G., Fletcher, R., & Cohn, J. (1996). Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): Baseline characteristics, prognosis and response to therapy in the vasodilator in heart failure trials (V-HeFT). Journal of the American College of Cardiologists, 27, 642-649.
17. Carson, P., Ziesche, S., Johnson, G., & Cohn, J. N. (1999). Racial differences in response to therapy for heart failure: Analysis of the vasodilator heart failure trials. Journal of Cardiac Failure, 5, 178-187.
18. Chikhi, L., Destro-Bisol, G., Pascali, V., Baravelli, V., Dobosz, M., & Barbujani, G. (1998). Clinal variation in the nuclear DNA of Europeans. Human Biology, 70, 643-657.
19. Churchill, E. (1997). Supplement: Genes and society: Puzzles, promises and policy. Annals of the American Academy of Political and Social Science, 549, 173-184.
20. Cohn, J. N. (1988). Effect of vasodilator therapy on mortality in chronic congestive heart failure. European Heart Journal, 9 (Suppl. A), 171-173.
21. Cohn, J. N. (1993). The vasodilator heart failure trials (V-HeFT), mechanistic data from the VA cooperative studies-Introduction. Circulation, 87(Suppl. 6), 11-14.
22. Cohn, J. N. (1994). Vasodilators in heart failure, conclusions from V-HeFT II and rationale for V-HeFT III. Drugs, 47(Suppl. 4), 47-58.
23. Cohn, J. N. (1995). Plasma norepinephrine and mortality. Clinical Cardiology, 18(3), 9-12.
24. Cohn, J. N., & Johnson, G. (1990). Heart failure with normal ejection fraction. Circulation, 81(Suppl. 2), 48-53.
25. Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., etal. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure, results of a veterans administration cooperative study. The New England Journal of Medicine, 314, 1547-1552.
26. Cohn, J. N., Johnson, G. R., Shabetai, R., Loeb, H., Tristani, F., Rector, T., etal. (1993). Ejection fraction, peak exercise oxygenation consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation, 87(Suppl. 6), 15-16.
27. Cohn, J. N., Ziesche, S., Smith, R., Anand, I., Dunkman, W. B., Loeb, H., etal. (1997). Effect of the calcium antagonist felodipine as supplementary therapy in patients with chronic heart failure treated with enalapril: V-HeFT III, vasodilator heart failure trial (V-HeFT) study group. Circulation, 96(3), 856-863.
28. Collins, F. S. (2004). What we do and don't know about "race,""ethnicity"genetics and health at the dawn of the genome era. Nature Genetics, 36(11), 13-15.
29. Cooper, R. S., Kaufman, J. S., & Ward, R. (2003). Race and genomics. New England Journal of Medicine, 348, 1166-1170.
30. Dunkman, W. B., Johnson, G. R., Carson, P. E., Bhat, G., Farrell, L., & Cohn, J. N. (1993). Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation, 87 (6 Supplement), 94-101.
31. Elkayam, U., & Bitar, F. (2005). Effects of nitrates and hydrazaline in heart failure: Clinical evidence before the African American heart failure trial. American Journal of Cardiology, 96(7B), 37-43.
32. Except as laboratory technicians, Blacks had no role in the sequencing of the human genome. (2001). Journal of Blacks in Higher Education, 33(Autumn), 16-18.
33. Fairchild, A. L., & Bayer, R. (1999). Uses and abuses of Tuskegee. Science, 284 (May), 919-921.
34. Feagin, J. R. (1978). Discrimination American style: Institutional racism and sexism. Englewood Cliffs, NJ: Prentice-Hall.
35. Feagin, J. R. (2001). Racist America: Roots, current realities and future reparations. New York: Routledge.
36. Funke, O. (1985). Biopolitics and public policy: Controlling biotechnology. PS, 18, 69-77.
37. Hardin, R. (1988). Morality within the limits of reason. Chicago: Chicago University Press.
38. Hardin, R. (1989). Ethics and stochastic processes. Social Philosophy and Policy, 7, 69-80.
39. Hardin, R. (2003). Indeterminacy and Society. Princeton, NJ: Princeton University Press.
40. Hardy, C. M., Wynn, T. A., Huckaby, F., Lisovicz, N., & White-Johnson, F. (2005). African American community health advisors trained as research partners: Recruitment and training. Family and Community Health, 28(1), 28-40.
41. Helmuth, L. (2000). NIH, under pressure, boosts minority health research. Science, 288, 596-597.
42. Iohom, G., Fitzgerald, D., & Cunningham, A. J. (2004). Principles of pharmacogenetics-implications for the anaesthetist. British Journal of Anaesthesia, 93, 440-450.
43. Jeffries, S. K., Choi, W., Butler, J., Harris, K. J., & Ahluwalia, J. S. (2005). Strategies for recruiting African American residents of public housing developments into a randomized controlled trial. Ethnicity and Disease, 15, 773-778.
44. Johnson, R. E., Green, B. L., Anderson-Lewis, C., & Wynn, T. A. (2005). Community health advisors as research partners: An evaluation of the training and activities. Family and Community Health, 28(1), 41-50.
45. Kahn, J. (2003). Getting the numbers right: Statistical mischief and racial profiling in heart failure research. Perspectives in Biology and Medicine, 46, 473-483.
46. Kahn, J. (2004). How a drug becomes "Ethnic": Law, commerce and the production of racial categories in medicine. Yale Journal of Health Policy, Law and Ethics, 4, 1-46.
47. Kahn, J. (2005a). Ethnic drugs. Hastings Center Report, 35, 1.
48. Kahn, J. (2005b). Misreading race and genomics after BiDil. Nature Genetics, 37, 655-666.
49. Kaplan, J. B., & Bennet, T. (2003). Use of race and ethnicity in biomedical publication. Journal of the American Medical Association, 289, 2709-2716.
50. Kittles, R. A., & Weiss, K. M. (2003). Race, ancestry and genes: Implications for defining disease risk. Annual Review of Genomics and Human Genetics, 4, 33-67.
51. LaVeist, T. A. (2002). Race, ethnicity and health: A public health reader. San Francisco: Jossey-Bass.
52. LaVeist, T. A. (2005). Minority populations and health: An introduction to health disparities in the United States. San Francisco: Jossey-Bass.
53. Lee, S. S-J. (2005). Personalized medicine and pharmacogenomics: Ethical and social challenges. Future Medicine, 2(1), 29-35.
54. Lee, S. S-J., Mountain, J., & Koenig, B. A. (2001). The meanings of "race"in the new genomics: Implications for health disparities research. Yale Journal of Health Policy, Law and Ethics, 1, 33-75.
55. Linder, M. W., Prough, R., Valdes, R., Jr. (1997). Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency. Clinical Chemistry, 43, 254-266.
56. Link, B. G. & Phelan, J. C. (2005). Fundamental sources of health inequalities. In D. Mechanic, L. B. Rogut, D. C. Colby, & J. R. Knickman (Eds.), Policy challenges in modern health care (pp. 71-84). New Brunswick, NJ: Rutgers University Press.
57. Loeb, H. S., Johnson, G., Henrick, A., Smith, R., Wilson, J., Cremo, R., etal. (1993). Effect of enalapril, hydrazaline plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive hearth failure. Circulation, 87(Suppl. 6), 78-87.
58. Masters, R. D. (1989). The nature of politics. New Haven, CT: Yale University Press.
59. Masters, R. D. (1993). Beyond relativism. Hanover, NH: University Press of New England.
60. Molnar, S. (2001). Human variation, races, types and ethnic groups (5th ed.). Upper Saddle River, NJ: Prentice Hall.
61. Moreno-John, G., Gachie, A., Fleming, C. M., Nápoles-Springer, A., Mutran, E., Manson, S. M., etal. (2004). Ethnic minority older adults participating in clinical research: Developing trust. Journal of Aging and Health, 16(Suppl.), 93-123.
62. Mullins, C. D., Blatt, L., Gbarayor, C. M., Yang, H. W., & Banquet, C. (2005). Health disparities: A barrier to high quality care. American Journal of Health System Pharmacy, 62, 1873-1882.
63. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979). The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. Washington, DC: Author.
64. Newman, P. A., Duan, N., Roberts, K. J., Seiden, D., Rudy, E. T., Swendeman, D., etal. (2006). HIV vaccine trial participation among ethnic minority communities: Barriers, motivators, and implications for recruitment. Journal of Acquired Immune Deficiency Syndrome, 41, 210-217.
65. Olifi, E., etal. (2005). The community physician's network (CPN): An academic-community partnership to eliminate healthcare disparities. Ethnicity and Disease, 15(Suppl. 4), 124-127.
66. Olson, S. (2003). Mapping human history: Genes race and our common origins. New York: Houghton-Mifflin.
67. Ossorio, P., & Duster, T. (2005). Race and genetics: Controversies in biomedical, behavioral and forensic sciences. American Psychologist, 2005, 115-128.
68. Parra, E. J., Kittles, R. A., & Shriver, M. D. (2004). Implications of correlations between skin color and genetic ancestry for biomedical research. Nature Genetics, 36(Suppl. 1), 54-60.
69. Puckrein, G., & Yancy, C. W. (2005). BiDil's impact. Nature Biotechnology, 23, 1343.
70. Rahemtulla, T., & Bhopal, R. (2006). Pharmacogenetics and ethnically targeted therapies: New drug BiDil marks the return of biology to the debate about race and ethnicity. British Medical Journal, 330, 1036-1037.
71. Resnik, D. B. (2007). Are the new EPA regulations concerning intentional exposure studies involving children overprotective? IRB: Ethics and Human Research, 29(5), 15-19.
72. Rosenbaum, S., & Teitelbaum, J. (2005). Addressing racial inequality in health care. In D. Mechanic, L. B. Rogut, D. C. Colby, & J. R. Knickman (Eds.), Policy challenges in modern health care. New Brunswick, NJ: Rutgers University Press.
73. Safrin, S. (2004). Hyperownership in a time of biotechnological promise: The international conflict to control the building blocks of life. The American Journal of International Law, 98, 641-685.
74. Sankar, P., & Kahn, J. (2005). BiDil: Race medicine or race marketing? Health Affairs, July-December, Supplementary Webexclusives, W5-455-W463.
75. Sankar, P., Cho, M. K., Condit, C. M., Hunt, L. M., Koenig, B., Marshall, P., etal. (2004). Genetic research and health disparities. Journal of the American Medical Association, 291, 2985-2989.
76. Schubert, G. (1991). Sexual politics and political feminism. Greenwich, CT: JAI Press.
77. Service, R. F. (2005). From genome to pill: A new medicine for African Americans with heart failure hints at what the drug industry sees as the enormous payoff from pharmacogenomics. Science, 308, 1858-1860.
78. Sherman, L. A., Temple, R., & Merkatz, R. B. (1995). Women in clinical trials: An FDA perspective. Science, 269 (August), 793-795.
79. Somit, A. (1968). Toward a more biologically-oriented political science. Midwest Journal of Political Science, 12, 550-567.
80. Somit, A., & Peterson, S. A. (1990). Biopolitics and mainstream political science. DeKalb, IL: Program for Biosocial Research.
81. Somit, A., & Peterson, S. A. (Eds.). (1996). Research in biopolitics. Greenwich, CT: JAI Press.
82. Somit, A., & Peterson, S. A. (1997). Darwinism, dominance and democracy. Westport, CT: Praeger.
83. Somit, A., & Peterson, S. A. (1998). Biopolitics after three decades - a balance sheet. British Journal of Political Science, 28, 559-571.
84. Somit, A., & Peterson, S. A. (1999). Rational choice and biopolitics: A (Darwinian) tale of two theories. PS: Political Science and Politics, 32, 39-44.
85. Somit, A., Peterson, S. A., Richardson, W., & Goldfischer, S. W. (1980). The literature of biopolitics (2nd ed.). DeKalb, IL: Center for Biopolitical Research.
86. Vivian, E. M. (2006). Should drug therapy be personalized based on race? The Annals of Pharmacotherapy, 40, 550-552.
87. Voluntary prescription drug care benefit. (2005). 42 C.F.R.§ 3.578.
88. Watts, M., (Ed.). (1981). Biopolitics: Ethnological and physiological approaches. San Francisco: Jossey-Bass.
89. Williams, D. R. (2005). Patterns and causes of disparities in health. In D. Mechanic, L. B. Rogut, D. C. Colby, & J. R. Knickman (Eds.), Policy challenges in modern health care. New Brunswick, NJ: Rutgers University Press.
90. Yancy, C. W. (2000). Heart failure in African Americans: A cardiovascular enigma. Journal of Cardiac Failure, 6, 183-186.
91. Ziesche, S., et al. (1993). Hydrazaline and isosorbide dinitrate combination improves exercise tolerance in heart failure. Circulation, 87(Suppl. 6), 65-74.